New research conducted by a team of experts from Flinders University and international collaborators has shed light on the connection between dangerous PF4 antibodies in vaccine-induced thrombosis (VITT) and similar conditions resulting from common cold infections. The findings reveal that these antibodies share identical molecular structures, which has significant implications for future vaccine development and disease management.
During the peak of the COVID-19 pandemic in 2021, VITT emerged as a new condition associated with adenovirus vector-based vaccines, such as the Oxford-AstraZeneca vaccine. Researchers discovered that VITT is caused by a highly harmful blood autoantibody targeting a protein called platelet factor 4 (PF4). Remarkably, separate research in 2023 identified a similar disorder with the same PF4 antibody arising from natural adenovirus infections, sometimes resulting in fatalities.
This groundbreaking research was led by Flinders University researchers Dr. Jing Jing Wang and Professor Tom Gordon, who previously decoded the molecular makeup of the PF4 antibody and identified a genetic risk factor related to an antibody gene called IGLV3.21*02.
Collaborating with international researchers, the Flinders team found that the PF4 antibodies in both vaccine-related VITT and classic adenoviral vectored VITT share identical molecular signatures. Dr. Wang emphasized that these findings will not only enhance vaccine development but also provide insights into the common triggers of pathological antibodies in viruses and vaccines.
The research, published in the prestigious New England Journal of Medicine, highlights the importance of understanding the shared pathways and genetic risk factors of these disorders. Lessons learned from VITT are applicable to rare cases of blood clotting after adenovirus infections, with implications for both disease management and future vaccine strategies.
